Ruppin Sebastian, Protzel Chris, Klebingat Klaus-Jürgen, Hakenberg Oliver W
Department of Urology, Ernst Moritz Arndt University of Greifswald, Greifswald, Germany.
Eur Urol. 2009 Apr;55(4):986-8; quiz 988. doi: 10.1016/j.eururo.2008.10.027. Epub 2008 Oct 23.
Treatment options for patients with end-stage renal disease (ESRD) and metastatic renal cell carcinoma (mRCC) are limited. We report the case of a 69-yr-old male who was treated with sorafenib after failure of immunotherapy. The treatment has resulted in remission with stable disease for 13 mo so far. Sorafenib seems to be a safe treatment option for patients with ESRD and mRCC, but further studies are required.
终末期肾病（ESRD）和转移性肾细胞癌（mRCC）患者的治疗选择有限。我们报告了一例69岁男性患者，其免疫治疗失败后接受了索拉非尼治疗。该治疗目前已使病情缓解并稳定了13个月。索拉非尼似乎是ESRD和mRCC患者的一种安全治疗选择，但仍需进一步研究。
